Moderna Stock Soars After Positive Results for Cancer Vaccine
Moderna's stock jumped nearly 130% after positive Phase 3 results for a personalized cancer vaccine developed with Merck. This vaccine, "Intismeran autogene," showed that combining it with Keytruda significantly lowered the risk of recurrence or death in melanoma patients. Experts view this success as a major growth driver beyond Moderna's COVID-19 vaccines.
Moderna's shares recorded a dramatic increase following the release of positive study results for a novel, personalized cancer vaccine developed in collaboration with Merck. The news caused Moderna's stock price to jump by almost 130%. The focus of the positive announcement is on this vaccine, named "Intismeran autogene," which is specifically tailored to the genetic structure of the tumor and was developed in partnership with Merck. A Phase 3 study with 1100 patients with malignant melanoma showed promising results, particularly as the combination of this vaccine with Keytruda significantly reduced the risk of recurrence or death. Experts view this success as a major breakthrough for Moderna's future market role, allowing the company to grow beyond its existing portfolio of COVID-19 vaccines.